News

NOTTINGHAM, UK – April 16th, 2024

IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, today announced the appointment of Dr Anker Lundemose to its Board of Directors, as an independent non-executive Director. This follows the recent closing of a £7.5 million Seed funding in late February.

Commenting on the appointment, Paul Edwards, Chairman of IsomAb Ltd, said: “On behalf of the Board I am pleased to welcome Anker as an independent director. His expertise and his deep industry experience will be a valuable addition to our team of seasoned investors on the Board as well as to our CEO and executive team and we look forward to benefitting from his insights.”

Dr Anker Lundemose said: “I am very happy to join IsomAb Ltd as an independent director, and I look forward to working closely with my new board colleagues and the CEO to help the Company leverage its potential for the benefit of patients and the stakeholders. I have a long-standing interest in both metabolic and cardiovascular diseases and am excited about the potential of ISM-001 to bring real improvements in patient treatment in these fields.”

Anker Lundemose, who qualified with a medical degree from Aarhus University in Denmark, is currently Chief Executive Officer of MISSION Therapeutics in Cambridge, UK. He has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology, diabetes and anti-infectives. He has a comprehensive international experience and network and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech start-ups, large biotech and big pharma, as well as an initial career in academia.